Edunn Biotechnology, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Edunn Biotechnology, Inc. - overview
Location
St. Louis, MO, US
Primary Industry
Biotechnology
About
Based in Missouri, US, and Edunn Biotechnology, Inc. operates as a healthcare company providing drugs and therapies for curing Alzheimer's disease and to treat Down syndrome. In January 2009, Alzheimer's Drug Discovery Foundation invested USD 0. 20 million in Edunn Biotechnology, Inc.
Edunn Biotechnology, Inc. developed EDN-OL1, which is an oligonucleotide-based drug for halting and reversing the progression of AD in animal models. It reduces the production of amyloid beta proteins found in the brain and believed to cause AD. The company offers nervous system (CNS) drugs to treating Alzheimer's disease, Down syndrome, stroke and traumatic brain injury.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.